Proscia Concentriq vs Tempus Digital Pathology
Proscia Concentriq and Tempus Digital Pathology both compete in pathology, but answer different questions. Proscia Concentriq is our pick for pharma R&D labs: Used by 16/20 top pharma. $130M total funding. Tempus Digital Pathology earns the Paige acquisition (Aug 2025) slot: Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI. The right choice depends on whether your priority is pharma r&d labs or paige acquisition (aug 2025).
- Pathology
- 02
- May 23, 2026
Tempus Digital Pathology
by Tempus AI
Paige Predict 123-biomarker pan-cancer suite (Tempus acquired Paige 2025).
- Enterprise + per-test.
- FDA 510(k) / CE-IVDR
How Proscia Concentriq and Tempus Digital Pathology compare
Pricing, compliance, and integrations sourced from vendor documentation. Verified May 23, 2026.
| Spec | Proscia Concentriq | Tempus Digital Pathology |
|---|---|---|
| Pricing | Enterprise. | Enterprise + per-test. |
| Free tier | Yes | Yes |
| HIPAA | No / unverified | No / unverified |
| SOC 2 Type II | No / unverified | No / unverified |
| EHR integrations | Not specified | Not specified |
| Founded | — | — |
| HQ | — | US |
| Best for | Best for pharma R&D labs | Best after Paige acquisition (Aug 2025) |
Scroll horizontally to see both columns.
When to pick each one
Best for pharma R&D labs
Used by 16/20 top pharma. $130M total funding.
- IMS platform + AI marketplace
- Strongest pharma R&D footprint
Best after Paige acquisition (Aug 2025)
Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI.
- NASDAQ:TEM
- Most clinical-validation depth
- FDA + CE-IVDR cleared modules
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.
/best-ai-pathology